Literature DB >> 32826126

Use of Cigarettes and E-Cigarettes/Vaping Among Transgender People: Results From the 2015 U.S. Transgender Survey.

Luisa Kcomt1, Rebecca J Evans-Polce2, Phil T Veliz3, Carol J Boyd4, Sean E McCabe5.   

Abstract

INTRODUCTION: This study examines the demographic characteristics, transgender-specific factors, and discrimination experiences associated with current cigarette smoking, e-cigarette use/vaping, and dual use in a large sample of transgender people.
METHODS: This was a secondary analysis of the 2015 U.S. Transgender Survey (n=27,715). Conducted in 2019, logistic regression models were used to estimate the AORs and 95% CIs of current smoking, e-cigarette use/vaping, and dual use among transgender people.
RESULTS: Overall, 23.6% of respondents used cigarettes, 9.3% used e-cigarettes/vaping products, and 5.2% reported dual use within the past 30 days. Visually nonconforming individuals had greater odds (cigarettes: AOR=1.49, 95% CI=1.35, 1.65; e-cigarettes/vaping: AOR=1.43, 95% CI=1.25, 1.65; dual use: AOR=1.81, 95% CI=1.52, 2.15) than visually conforming individuals. Transgender people who had disclosed their transgender identity to their social networks had greater odds of cigarette smoking (AOR=1.30, 95% CI=1.17, 1.45), e-cigarette use/vaping (AOR=1.30, 95% CI=1.12, 1.52), and dual use (AOR=1.95, 95% CI=1.61, 2.35) than individuals who were out to none or some people within their networks. Experiencing discrimination (i.e., unequal treatment, verbal harassment, or physical assault) significantly increased the odds for cigarette smoking, e-cigarette use/vaping, and dual use. Transgender people who experienced all 3 types of discrimination had 2 times greater odds of current cigarette smoking (AOR=2.06, 95% CI=1.79, 2.37) and dual use (AOR=2.17, 95% CI=1.73, 2.74) than those who had not experienced discrimination.
CONCLUSIONS: Discrimination, visual nonconformity, and being out as transgender increased the odds of cigarette smoking, e-cigarette use/vaping, and dual use. This study informs disease prevention efforts for transgender populations with increased risks for these health behaviors.
Copyright © 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32826126      PMCID: PMC7508765          DOI: 10.1016/j.amepre.2020.03.027

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  33 in total

1.  Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative.

Authors:  Ronald C Kessler; Jennifer Greif Green; Michael J Gruber; Nancy A Sampson; Evelyn Bromet; Marius Cuitan; Toshi A Furukawa; Oye Gureje; Hristo Hinkov; Chi-Yi Hu; Carmen Lara; Sing Lee; Zeina Mneimneh; Landon Myer; Mark Oakley-Browne; Jose Posada-Villa; Rajesh Sagar; Maria Carmen Viana; Alan M Zaslavsky
Journal:  Int J Methods Psychiatr Res       Date:  2010-06       Impact factor: 4.035

2.  Sexual and gender minority cigarette smoking disparities: An analysis of 2016 Behavioral Risk Factor Surveillance System data.

Authors:  Leah Hoffman; Janine Delahanty; Sarah E Johnson; Xiaoquan Zhao
Journal:  Prev Med       Date:  2018-05-12       Impact factor: 4.018

3.  Trends in E-Cigarette, Cigarette, Cigar, and Smokeless Tobacco Use Among US Adolescent Cohorts, 2014-2018.

Authors:  Rebecca Evans-Polce; Phil Veliz; Carol J Boyd; Vita V McCabe; Sean Esteban McCabe
Journal:  Am J Public Health       Date:  2019-12-19       Impact factor: 9.308

4.  Sexual and gender minority young adults' smoking characteristics: Assessing differences by sexual orientation and gender identity.

Authors:  Erin A Vogel; Gary L Humfleet; Meredith Meacham; Judith J Prochaska; Danielle E Ramo
Journal:  Addict Behav       Date:  2019-03-05       Impact factor: 3.913

Review 5.  Tobacco use among sexual minorities in the USA, 1987 to May 2007: a systematic review.

Authors:  J G L Lee; G K Griffin; C L Melvin
Journal:  Tob Control       Date:  2009-02-10       Impact factor: 7.552

Review 6.  Tobacco smoking: the leading cause of preventable disease worldwide.

Authors:  Jonathan M Samet
Journal:  Thorac Surg Clin       Date:  2013-02-13       Impact factor: 1.750

7.  Tobacco Product Use Among Sexual Minority Adults: Findings From the 2012-2013 National Adult Tobacco Survey.

Authors:  Sarah E Johnson; Enver Holder-Hayes; Greta K Tessman; Brian A King; Tesfa Alexander; Xiaoquan Zhao
Journal:  Am J Prev Med       Date:  2015-10-31       Impact factor: 5.043

8.  JUUL and Combusted Cigarettes Comparably Impair Endothelial Function.

Authors:  Poonam Rao; Jiangtao Liu; Matthew L Springer
Journal:  Tob Regul Sci       Date:  2020-01

9.  Tobacco Use Among Transgender and Gender Non-conforming Adults in the United States.

Authors:  Christopher W Wheldon; Kara P Wiseman
Journal:  Tob Use Insights       Date:  2019-05-23

10.  Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury - United States, October 2019.

Authors:  David A Siegel; Tara C Jatlaoui; Emily H Koumans; Emily A Kiernan; Mark Layer; Jordan E Cates; Anne Kimball; David N Weissman; Emily E Petersen; Sarah Reagan-Steiner; Shana Godfred-Cato; Danielle Moulia; Erin Moritz; Jonathan D Lehnert; Jane Mitchko; Joel London; Sherif R Zaki; Brian A King; Christopher M Jones; Anita Patel; Dana Meaney Delman; Ram Koppaka
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-10-18       Impact factor: 17.586

View more
  9 in total

1.  Nicotine/tobacco use disparities among transgender and gender diverse adults: Findings from wave 4 PATH data.

Authors:  Ashlee N Sawyer; Rose S Bono; Bekir Kaplan; Alison B Breland
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.492

2.  Health and health care access in the US transgender population health (TransPop) survey.

Authors:  Jamie L Feldman; Winston Ekaprasetia Luhur; Jody L Herman; Tonia Poteat; Ilan H Meyer
Journal:  Andrology       Date:  2021-06-10       Impact factor: 3.842

3.  Vaping Disparities at the Intersection of Gender Identity and Race/Ethnicity in a Population-Based Sample of Adolescents.

Authors:  Jennifer K Felner; Jack Andrzejewski; David Strong; Talia Kieu; Madhumitha Ravindran; Heather L Corliss
Journal:  Nicotine Tob Res       Date:  2022-02-14       Impact factor: 5.825

4.  Preventing cardiovascular disease among sexual and gender minority persons.

Authors:  Carl Streed; Billy Caceres; Monica Mukherjee
Journal:  Heart       Date:  2021-02-16       Impact factor: 7.365

5.  Cardiovascular Disease in a Population-Based Sample of Transgender and Cisgender Adults.

Authors:  Tonia C Poteat; Shahrzad Divsalar; Carl G Streed; Jamie L Feldman; Walter O Bockting; Ilan H Meyer
Journal:  Am J Prev Med       Date:  2021-08-05       Impact factor: 6.604

Review 6.  Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association.

Authors:  Carl G Streed; Lauren B Beach; Billy A Caceres; Nadia L Dowshen; Kerrie L Moreau; Monica Mukherjee; Tonia Poteat; Asa Radix; Sari L Reisner; Vineeta Singh
Journal:  Circulation       Date:  2021-07-08       Impact factor: 39.918

7.  Differences in Quit Attempts, Successful Quits, Methods, and Motivations in a Longitudinal Cohort of Adult Tobacco Users by Sexual Orientation.

Authors:  Joanne G Patterson; Alice Hinton; Sarah E Cooper; Mary Ellen Wewers
Journal:  Nicotine Tob Res       Date:  2021-10-07       Impact factor: 5.825

8.  Cardiovascular disease in transgender people: recent research and emerging evidence.

Authors:  Paul J Connelly; Christian Delles
Journal:  Cardiovasc Res       Date:  2021-12-17       Impact factor: 10.787

Review 9.  Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults.

Authors:  Billy A Caceres; Melissa Bynon; Danny Doan; Nour Makarem; Amanda C McClain; Nicole VanKim
Journal:  Curr Atheroscler Rep       Date:  2022-02-02       Impact factor: 5.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.